Form 4: Royalty Pharma Director Vlad Coric Acquires Shares

Royalty Pharma Director Vlad Coric acquired 4,545 ordinary shares through an award of restricted stock units.

Summary

• Vlad Coric, a Director at Royalty Pharma plc, acquired 4,545 Class A Ordinary Shares.
• The acquisition occurred on June 5, 2026, and was made through an award of restricted stock units (RSUs).
• These RSUs are part of the Issuer's 2020 Independent Director Equity Incentive Plan.
• The award is scheduled to vest fully on the earlier of the one-year anniversary of the grant date or the date of the annual shareholders' meeting in the first calendar year following the grant date.
• Following this transaction, Coric beneficially owns 15,343 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard director award and not a significant personal investment or divestment.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The award of restricted stock units aligns director compensation with long-term company performance.
• The number of shares acquired (4,545) represents a modest increase in beneficial ownership for the director.

Future Outlook

The restricted stock units are scheduled to vest on the earlier of the one-year anniversary of the grant date or the date of the annual shareholders' meeting in the first calendar year following the grant date, subject to the terms of the plan and award agreement.

Industry Context

StockSavvy.ai notes that director share awards are a common practice in the pharmaceutical and biotechnology sectors to incentivize and retain key leadership, aligning their interests with those of shareholders.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of commitment, but the RSU award is a standard compensation mechanism.
• Employees: The RSU plan reflects the company's approach to executive and director compensation.
• Management: The award is part of the compensation structure for directors.

Next Steps

• Vesting of restricted stock units on the earlier of the one-year anniversary of the grant date or the date of the annual shareholders' meeting in the first calendar year following the grant date.

Key Dates

Keywords

Royalty Pharma, Vlad Coric, Form 4, SEC Filing, Director, Restricted Stock Units, Equity Incentive Plan, Share Acquisition